Phase I dose escalation study of IO-108, an anti-LILRB2 antibody, in patients with advanced solid tumors by Ying Zhu, Tao Huang, John Powderly, Aung Naing, Manish R Patel, Matthew H Taylor, Rong Deng, Kyu Hong, Luke Chung, Hongyu Tian, Wen Hong Lin, Paul Woodard, Nathan Siemers, Hong Xiang, Donna Valencia, X Charlene Liao, Xiao Min Schebye

Get full text